Collegium Pharmaceutical (NASDAQ:COLL) Hits New 12-Month Low – Here’s Why

Collegium Pharmaceutical, Inc. (NASDAQ:COLL)’s share price reached a new 52-week low on Monday . The company traded as low as $28.97 and last traded at $29.18, with a volume of 46245 shares changing hands. The stock had previously closed at $29.70.

Analyst Ratings Changes

Several research firms have weighed in on COLL. HC Wainwright raised their target price on Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, September 5th. Piper Sandler restated a “neutral” rating and set a $37.00 price target on shares of Collegium Pharmaceutical in a report on Friday, October 11th. Finally, StockNews.com lowered Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $42.60.

Collegium Pharmaceutical Stock Performance

The stock has a 50-day moving average of $32.30 and a 200 day moving average of $34.30. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. The firm has a market capitalization of $937.19 million, a P/E ratio of 12.53 and a beta of 0.80.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Foundry Partners LLC bought a new stake in shares of Collegium Pharmaceutical during the second quarter worth approximately $492,000. Penserra Capital Management LLC acquired a new position in shares of Collegium Pharmaceutical during the 3rd quarter worth about $757,000. Squarepoint Ops LLC boosted its stake in Collegium Pharmaceutical by 194.5% during the 2nd quarter. Squarepoint Ops LLC now owns 110,338 shares of the specialty pharmaceutical company’s stock worth $3,553,000 after acquiring an additional 72,874 shares during the last quarter. BOKF NA acquired a new position in shares of Collegium Pharmaceutical in the 2nd quarter valued at $490,000. Finally, Renaissance Technologies LLC raised its stake in Collegium Pharmaceutical by 8.0% during the 2nd quarter. Renaissance Technologies LLC now owns 1,531,498 shares of the specialty pharmaceutical company’s stock worth $49,314,000 after buying an additional 113,300 shares during the period.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.